Authors : Ting Wu, Xiufeng Yu, Linna Zhu and Yizhen Wang
Abstract: SR141716 is the antagonist of Cannabinoid Receptor type 1 (CB1). The study was conducted to investigate the effects of SR141716 on body weight gain, body fat, hepatic fat deposit and Carnitine Palmitoyltransferase 1 (CPT1) expression in obese Sprague-Dawley (SD) rats induced by High Fat Diet (HFD). Twenty four SD rats were randomly allocated to three groups: the Normal Diet (ND) as control group, the High Fat Diet (HFD) and SR141716 treated HFD-diet (SFD) animals as experimental groups. Plasma was collected immediately for following plasma indexes determination. Liver samples were flash frozen in lipid nitrogen and stored at –80°C until use for following experiments. Compared with the ND group, HFD significantly increased the body weight gain (p<0.05), total viscera fat pad (p<0.05) and hepatic Triglyceride (TG) (p<0.05) in rats while SR141716 significantly suppressed these effects (p<0.05). Furthermore, hepatic CPT1 mRNA level was significant decreased by HFD (p<0.05). Hepatic CPT1 and PPARγ mRNA level were significantly suppressed by SR141716 accompany with CB1 mRNA expression decrease (p<0.05). The results indicated that SR141716 can significantly suppress the excess hepatic adipose deposit induced by HFD in rats. During this process, the pivotal role of CB1 in hepatic fat deposit may considerably to a large extent be due to modulation of CPT1 expression through PPARγ. However, the accurate mechanism remains to be elucidated in the future.
Ting Wu, Xiufeng Yu, Linna Zhu and Yizhen Wang, 2012. Cannabinoid Receptor Type 1 (CB1) Antagonist, SR141716 Suppresses Hepatic CPT1 Gene Expression in Rat. Journal of Animal and Veterinary Advances, 11: 2969-2975.